$SHILPAMED Shilpa Medicare Ltd. reported a strong Q4 FY26 performance

Shilpa Medicare Ltd. reported a strong Q4 FY26 performance with revenue and profitability improving sharply year‑on‑year, driven by oncology formulations and API exports. 📊 Shilpa Medicare Q4 FY26 Results Highlights Metric Q4 FY26 Q4 FY25 Change YoY Revenue from Operations ₹385 crore ₹312 crore +23 % Net Profit (Consolidated) ₹52 crore ₹31 crore +68 % EBITDA ₹86 crore ₹61 crore +41 % EBITDA Margin 22.3 % 19.5 % Improved by 280 bps EPS ₹6.4 ₹3.8 +68 % 🧩 Key Insights Oncology Formulations: Strong growth in domestic and regulated‑market sales, especially in US and EU. API Exports: Recovery in demand for oncology and immunosuppressant APIs. R&D Focus: Increased investment in peptide and biosimilar development. Subsidiaries: Shilpa Therapeutics and Loba Chemie contributed positively to consolidated earnings. Debt Position: Net Debt reduced by ₹120 crore YoY, improving leverage ratios. 💡 Investor Takeaways Profitability Momentum: Margins expanded on better product mix and operating efficiency. Pipeline Strength: 20+ products under development for regulated markets. Positive Outlook: Management expects double‑digit growth in FY27 driven by oncology and peptide segments.